Underwriters fully exercise overallotment option, adding $30M to MoonLake's recent raise
MLTX has more than doubled off its 52-week low of $5.95.
Summary
MoonLake Immunotherapeutics announced that underwriters exercised their overallotment option in full, generating an additional $30 million in gross proceeds from the sale of 1.5 million shares. Total offering proceeds now stand at $230 million.
Key Events · Financing and Capital Events · MLTX
-
Overallotment Option Exercised in Full
Underwriters purchased an additional 1,500,000 Class A ordinary shares at the offering price, generating $30.0 million in gross proceeds before discounts and expenses.
-
Total Offering Size Increased to $230M
Combined with the initial $200 million offering, total gross proceeds reach $230 million, providing substantial capital for operations and pipeline advancement.
-
Closing Completed
The sale of the additional shares closed on July 14, 2026, with the company receiving the proceeds.
-
Prior Offering Context
This follows the $200 million public offering priced on June 24, 2026, which included a 30-day option for underwriters to purchase up to an additional 15% of the shares sold.
Analysis · MLTX · Life Sciences
The underwriters of MoonLake's recent public offering exercised their option to purchase an additional 1.5 million shares, bringing total gross proceeds to $230 million. This adds to the $200 million raised just weeks ago, further strengthening the balance sheet ahead of the planned Q3 2026 BLA submission for sonelokimab. While dilutive, the additional capital provides greater financial flexibility and reduces near-term financing risk.
At the time of this filing, MLTX was trading at $20.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $5.95 to $62.75. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.